By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Catabasis Pharmaceuticals, Inc. 

161 First Street
Suite 1A
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-349-1971 Fax: 617-273-2637


SEARCH JOBS


Industry
Pharmaceutical






Company News
Catabasis (CATB)To Present Edasalonexent (CAT-1004), An Oral Agent Targeting NF-Kb: Movedmdsm Trial In Duchenne Muscular Dystrophy (DMD) At The 2016 PPMD Annual Connect Conference 6/20/2016 10:18:03 AM
Catabasis (CATB) To Present Edasalonexent (CAT-1004), An Oral Agent Targeting NF-Kb: Movedmd Trial In Duchenne Muscular Dystrophy (DMD) At The 2016 PPMD Annual Connect Conference 6/20/2016 9:35:46 AM
CureDuchenne And Catabasis (CATB) To Host A Webinar To Review Information On Edasalonexent (CAT-1004) And The MoveDMD Trial On June 22, 2016 6/14/2016 8:22:44 AM
Catabasis (CATB) And Parent Project Muscular Dystrophy To Host A Webinar On MoveDMD: A Clinical Trial Of Edasalonexent (CAT-1004) In Boys With Duchenne Muscular Dystrophy 6/8/2016 8:34:31 AM
Catabasis (CATB) Craters as Cholesterol Drug Flunks Mid-Stage Study 6/8/2016 5:57:53 AM
Catabasis Pharma To Present Pre-Clinical Data Supporting CAT-2054 As A Potential Treatment For Nonalcoholic Steatohepatitis (NASH) At Digestive Disease Week 2016 5/16/2016 10:30:12 AM
Catabasis Pharma To Present CAT-2054, A Potential Treatment For Nonalcoholic Steatohepatitis (NASH) And Hypercholesterolemia, At The National Lipid Association 2016 Scientific Sessions 5/16/2016 10:28:53 AM
Catabasis Pharma Reports First Quarter 2016 Financial Results And Recent Corporate Highlights 5/13/2016 8:49:06 AM
Catabasis Pharma To Report First Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, May 12 4/28/2016 11:20:13 AM
Catabasis Pharma Initiates Part B Of The MoveDMD Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 4/12/2016 10:15:55 AM
12345678910
//-->